Melanie Paff

1.3k total citations
31 papers, 751 citations indexed

About

Melanie Paff is a scholar working on Epidemiology, Hepatology and Infectious Diseases. According to data from OpenAlex, Melanie Paff has authored 31 papers receiving a total of 751 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Epidemiology, 12 papers in Hepatology and 8 papers in Infectious Diseases. Recurrent topics in Melanie Paff's work include Hepatitis B Virus Studies (16 papers), Hepatitis C virus research (12 papers) and HIV/AIDS drug development and treatment (6 papers). Melanie Paff is often cited by papers focused on Hepatitis B Virus Studies (16 papers), Hepatitis C virus research (12 papers) and HIV/AIDS drug development and treatment (6 papers). Melanie Paff collaborates with scholars based in United States, United Kingdom and China. Melanie Paff's co-authors include Donald J. Nelson, D R Averett, Ronna E. Dornsife, P A Furman, Lloyd Frick, M. Davis, James A. Fyfe, Lawrence J. Wilson, Dennis C. Liotta and John E. Reardon and has published in prestigious journals such as Nature Medicine, Biochemistry and Clinical Infectious Diseases.

In The Last Decade

Melanie Paff

30 papers receiving 730 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Melanie Paff United States	13	386	301	295	247	104	31	751
Shirish Paranjpe United States	19	284 0.7×	254 0.8×	139 0.5×	454 1.8×	95 0.9×	30	963
Sonal Rajyaguru United States	18	550 1.4×	272 0.9×	589 2.0×	728 2.9×	95 0.9×	25	1.1k
Rakesh Tripathi United States	20	859 2.2×	270 0.9×	579 2.0×	1.0k 4.1×	59 0.6×	43	1.5k
Jan Martin Berke Belgium	16	712 1.8×	183 0.6×	340 1.2×	764 3.1×	58 0.6×	31	1.0k
Gabrielle Heilek United States	15	182 0.5×	177 0.6×	321 1.1×	149 0.6×	199 1.9×	32	798
John Wickersham United States	8	216 0.6×	314 1.0×	126 0.4×	340 1.4×	34 0.3×	10	724
Ronna E. Dornsife United States	16	559 1.4×	412 1.4×	613 2.1×	93 0.4×	426 4.1×	25	1.4k
Stephen M. Shaw United States	17	219 0.6×	356 1.2×	159 0.5×	94 0.4×	135 1.3×	39	1.0k
Erika Cretton-Scott United States	8	207 0.5×	125 0.4×	234 0.8×	209 0.8×	45 0.4×	10	423
Julie Q. Hang United States	16	228 0.6×	257 0.9×	340 1.2×	238 1.0×	165 1.6×	20	718

Countries citing papers authored by Melanie Paff

Since Specialization

Citations

This map shows the geographic impact of Melanie Paff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Melanie Paff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Melanie Paff more than expected).

Fields of papers citing papers by Melanie Paff

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Melanie Paff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Melanie Paff. The network helps show where Melanie Paff may publish in the future.

Co-authorship network of co-authors of Melanie Paff

This figure shows the co-authorship network connecting the top 25 collaborators of Melanie Paff. A scholar is included among the top collaborators of Melanie Paff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Melanie Paff. Melanie Paff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Han, Kelong, et al.. (2025). Lack of Pharmacokinetic Drug–Drug Interactions Between Bepirovirsen and Nucleos(t)ide Analogs. Clinical Pharmacology in Drug Development. 14(4). 281–291. 2 indexed citations

Joshi, Shilpy, Johannes Freudenberg, Jagdeep Singh, et al.. (2025). Bepirovirsen immune mechanism of action may potentiate infected hepatocyte killing: Indirect evidence from B-together peripheral longitudinal biomarker analysis. Digestive and Liver Disease. 57. S27–S27. 2 indexed citations

Joshi, Shilpy, Johannes Freudenberg, William T. Jordan, et al.. (2025). Immunomodulation by bepirovirsen may induce killing of infected hepatocytes (B-Together study). Hepatology International. 20(1). 46–58.

Cremer, Jennifer, Robert C. Elston, Fiona Campbell, et al.. (2023). B-Clear Phase 2b Study Design: Establishing the Efficacy and Safety of Bepirovirsen in Patients with Chronic Hepatitis B Virus Infection. Advances in Therapy. 40(9). 4101–4110. 1 indexed citations

Bouquet, Jérôme, Robert C. Elston, Phil Yates, et al.. (2023). Frequency of bepirovirsen binding site nucleotide polymorphisms at baseline and impact on end of treatment response to bepirovirsen (Phase 2b B-Clear study). Journal of Hepatology. 78. S1162–S1162. 1 indexed citations

Salaun, Bruno, et al.. (2023). Cell-mediated immunity analysis to assess the characteristics of immune response to bepirovirsen: Examples from the B-Clear study. Journal of Hepatology. 78. S1167–S1169. 4 indexed citations

Delahaye, Jared L., et al.. (2022). Combination treatment of a PAPD5/7 inhibitor with an antisense oligonucleotide bepirovirsen with concurrent dosing shows additive HBsAg decreases in the AAV-HBV mouse model. Journal of Hepatology. 77. S880–S880. 1 indexed citations

Yuen, Man‐Fung, Jeong Heo, Jung‐Hwan Yoon, et al.. (2021). Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B: a phase 2 randomized controlled trial. Nature Medicine. 27(10). 1725–1734. 102 indexed citations

Han, Kelong, Jennifer Cremer, Robert C. Elston, et al.. (2019). A Randomized, Double‐Blind, Placebo‐Controlled, First‐Time‐in‐Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of GSK3389404 in Healthy Subjects. Clinical Pharmacology in Drug Development. 8(6). 790–801. 34 indexed citations

10.

Gardner, Stephen D., Jae Bum Kim, Víctor A. López, et al.. (2017). GSK2878175, a pan‐genotypic non‐nucleoside NS5B polymerase inhibitor, in healthy and treatment‐naïve chronic hepatitis C subjects. Journal of Viral Hepatitis. 25(1). 19–27. 10 indexed citations

11.

Rodriguez, Carlos O., William Plunkett, Melanie Paff, et al.. (2000). High-performance liquid chromatography method for the determination and quantitation of arabinosylguanine triphosphate and fludarabine triphosphate in human cells. Journal of Chromatography B Biomedical Sciences and Applications. 745(2). 421–430. 45 indexed citations

12.

Bading, James R., Antranik Shahinian, Melanie Paff, Paul B. Yoo, & David W. Hsia. (2000). Validation of fluorouracil metabolite analysis in excised tumor. Biochemical Pharmacology. 60(7). 963–967. 5 indexed citations

13.

Paff, Melanie, David P. Baccanari, Stephen T. Davis, et al.. (2000). Preclinical Development of Eniluracil: Enhancing the Therapeutic Index and Dosing Convenience of 5-Fluorouracil. Investigational New Drugs. 18(4). 365–371. 9 indexed citations

14.

Cullen, John M., M G Davis, Sandra E. Dunn, et al.. (1997). In vivo antiviral activity and pharmacokinetics of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine in woodchuck hepatitis virus-infected woodchucks. Antimicrobial Agents and Chemotherapy. 41(10). 2076–2082. 42 indexed citations

15.

Condreay, Lynn D., J. Patrick Condreay, Robert W. Jansen, Melanie Paff, & D R Averett. (1996). (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine (524W91) inhibits hepatitis B virus replication in primary human hepatocytes. Antimicrobial Agents and Chemotherapy. 40(2). 520–523. 20 indexed citations

16.

Clair, M H St, John E. Reardon, Harvey C. Krasny, et al.. (1995). Antiviral, metabolic, and pharmacokinetic properties of the isomeric dideoxynucleoside 4(S)-(6-amino-9H-purin-9-yl)tetrahydro-2(S)-furanmethanol. Antimicrobial Agents and Chemotherapy. 39(9). 1993–1999. 44 indexed citations

17.

Paff, Melanie, et al.. (1994). Pharmacokinetics and metabolism of 5-ethynyluracil, an inhibitor of 5-fluorouracil catabolism, in male CD-1 mice. 35. 321. 1 indexed citations

18.

Condreay, Lynn D., Robert W. Jansen, Lance C. Johnson, et al.. (1994). Evaluation of the potent anti-hepatitis B virus agent (-) cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine in a novel in vivo model. Antimicrobial Agents and Chemotherapy. 38(3). 616–619. 33 indexed citations

19.

Paff, Melanie & Daniel Fernandes. (1990). Synthesis and distribution of primer RNA in nuclei of CCRF-CEM leukemia cells. Biochemistry. 29(14). 3442–3450. 10 indexed citations

20.

Fernandes, Daniel, et al.. (1988). Effects of antileukemia agents on nuclear matrix-bound DNA replication in CCRF-CEM leukemia cells.. PubMed. 48(7). 1850–5. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact